Assessment of NETest Clinical Utility in a U.S. Registry-Based Study

Liu, Eric; Paulson, Scott; Gulati, Anthony; Freudman, Jon; Grosh, William W.; Kafer, Sheldon; Wickremesinghe, Prasanna; Salem, Ronald R.; Bodei, Lisa

doi:10.1634/theoncologist.2017-0623

Cited by 62 publications

(111 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients on SSA who were “responding” i.e., exhibited SD by imaging, exhibited a significantly ( p < 0.005) lower score (mean: 38) than those with image-demonstrable progression (mean score: 76). This is consistent with a recent study demonstrating that the NETest effectively identified SSA-treated patients who are responding to therapy [27]. …”

Section: Discussionsupporting

confidence: 92%

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: There are no effective biomarkers for the management of bronchopulmonary carcinoids (BPC). We examined the utility of a neuroendocrine multigene transcript “liquid biopsy” (NETest) in BPC for diagnosis and monitoring of the disease status. Aim: To independently validate the utility of the NETest in diagnosis and management of BPC in a multicenter, multinational, blinded study. Material and Methods: The study cohorts assessed were BPC (n = 99), healthy controls (n = 102), other lung neoplasia (n = 101) including adenocarcinomas (ACC) (n = 41), squamous cell carcinomas (SCC) (n = 37), small-cell lung cancer (SCLC) (n = 16), large-cell neuroendocrine carcinoma (LCNEC) (n = 7), and idiopathic pulmonary fibrosis (IPF) (n = 50). BPC were histologically classified as typical (TC) (n = 62) and atypical carcinoids (AC) (n = 37). BPC disease status determination was based on imaging and RECIST 1.1. NETest diagnostic metrics and disease status accuracy were evaluated. The upper limit of normal (NETest) was 20. Twenty matched tissue-blood pairs were also evaluated. Data are means ± SD. Results: NETest levels were significantly increased in BPC (45 ± 25) versus controls (9 ± 8; p < 0.0001). The area under the ROC curve was 0.96 ± 0.01. Accuracy, sensitivity, and specificity were: 92, 84, and 100%. NETest was also elevated in SCLC (42 ± 32) and LCNEC (28 ± 7). NETest accurately distinguished progressive (61 ± 26) from stable disease (35.5 ± 18; p < 0.0001). In BPC, NETest levels were elevated in metastatic disease irrespective of histology (AC: p < 0.02; TC: p = 0.0006). In nonendocrine lung cancers, ACC (18 ± 21) and SCC (12 ± 11) and benign disease (IPF) (18 ± 25) levels were significantly lower compared to BPC level (p < 0.001). Significant correlations were evident between paired tumor and blood samples for BPC (R: 0.83, p < 0.0001) and SCLC (R: 0.68) but not for SCC and ACC (R: 0.25–0.31). Conclusions: Elevated NETest levels are indicative of lung neuroendocrine neoplasia. NETest levels correlate with tumor tissue and imaging and accurately define clinical progression.

show abstract

Section: Discussionsupporting

confidence: 92%

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cost-effectiveness would be determined through changes (decreases) in imaging as has been recently noted. 46 The current study confirms that CgA has no role in predicting pNET disease recurrence. It has little accuracy, was the poorest feature for prediction and the OR (1.1) was no different to using no biomarker at all.…”

Section: Netest and Recurrence/nrsupporting

confidence: 72%

“…The frequency of testing would depend on the risk of progression. Cost‐effectiveness would be determined through changes (decreases) in imaging as has been recently noted …”

Section: Discussionmentioning

confidence: 99%

Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow‐up after curative surgical resection of well‐differentiated pancreatic neuroendocrine tumors

Genc

Jilesen

Dijkum

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The NETest was 93% positive, whereas single analytes were positive in ∼40%. In 2 other independent studies, a daily clinical practice registry audit (NCT02270567) of NEN [102] and a prospective, university-based study [100] the diagnostic accuracy of the NETest was confirmed to be 95-100%. Physician confidence in using monoanalytes like CgA or pancreastatin was low (accuracy 25-50%).…”

Section: T -Primary Tumourmentioning

confidence: 92%

“…Since the multigene assay captures diverse functional "omic" components of each tumour, the assay provides a broad molecular biological characterisation of tumour behaviour. In several studies comparing the NETest with single analyte measurements for diagnosis, the NETest is superior [101][102][103] (Fig. 2).…”

Section: T -Primary Tumourmentioning

confidence: 99%

Neuroendocrine Neoplasms of the Small Bowel and Pancreas

et al. 2019

Self Cite

View full text Add to dashboard Cite

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare, indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments in their incidence over the past decades render them increasingly clinically relevant, and at initial diagnosis many present with nodal and/or distant metastases (notably hepatic). The molecular pathogenesis of these tumours is increasingly yet incompletely understood. Those arising from the small bowel (SB) or pancreas typically occur sporadically; the latter may occur within the context of hereditary tumour predisposition syndromes. NENs can also be associated with endocrinopathy of hormonal hypersecretion. Tangible advances in the development of novel biomarkers, functional imaging modalities and therapy are especially applicable to this sub-set of tumours. The management of SB and pancreatic neuroendocrine tumours (NET) may be challenging, and often comprises a multidisciplinary approach wherein surgical, medical, interventional radiological and radiotherapeu-tic modalities are implemented. This review provides a comprehensive overview of the epidemiology, pathophysiology, diagnosis and treatment of SB and pancreatic NETs. Moreover, we provide an outlook of the future in these tumour types which will include the development of precision oncology frameworks for individualised therapy, multi-analyte predictive biomarkers, artificial intelligence-derived clinical decision support tools and elucidation of the role of the microbiome in NEN development and clinical behaviour.According to SEER version 18, SBNEN and PanNEN incidences are currently estimated at 1.2 and 0.7 per 100,000, respectively [5]. The overall 20-year duration prevalence of all NEN is estimated at 171,321; SBNEN constituting 32,122 patients with 3-fold fewer PanNEN (10,707) [5]. Possible attributable factors for this increase evolving epidemiology include increased use of endoscopy and also improvements in the sensitivity of widely used imaging modalities, leading to increased detection of early-stage, asymptomatic disease [5].The median overall survival (OS) for NEN (irrespective of site and grade) is 9.3 years [5]. For SB (median OS: 14 years), this ranges from 70 months (advanced disease with distant metastases) to 170 months (localised disease) and from 30 months (Grade 3) to 160 months (Grade 1). For pancreas (median OS: 3.6 years): 21 months (advanced) to 235 months (localised disease) and from 15 months (Grade 3) to 140 months (Grade 1) [5].Multivariable analyses have identified that ethnicity, age, differentiation, stage and site all have statistically significant correlations with survival. In general, Caucasian ethnicity, age (< 50 years) and localised, well-differentiated NEN exhibit the best survival. SB tumour patients are approximately 1.5 times more likely to survive longer than those with PanNEN [19]. Many of these correlations are self-evident since they pertain to degree of malignancy, disease duration and patient performance status.OS (median 5-year) app...

show abstract

Assessment of NETest Clinical Utility in a U.S. Registry-Based Study

Cited by 62 publications

References 34 publications

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow‐up after curative surgical resection of well‐differentiated pancreatic neuroendocrine tumors

Neuroendocrine Neoplasms of the Small Bowel and Pancreas

Contact Info

Product

Resources

About